Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Quanterix sells ultra-sensitive lab instruments and test kits that can detect tiny amounts of biological molecules, helping researchers and doctors study disease earlier and more precisely.
Quanterix makes machines and test kits that can sniff out incredibly tiny traces of proteins and other molecules in blood or other samples — amounts so small that older lab tests simply couldn't see them. Its customers are mostly scientists at pharmaceutical companies, research hospitals, and diagnostic labs who use this extra sensitivity to study diseases like Alzheimer's and cancer, where the early signals in the body are faint. The technology, called digital immunoassay, works by trapping individual molecules and counting them one at a time rather than measuring a big blob of them, which is how it reaches that extreme sensitivity.
The company sells its main instrument, the HD-1 and the newer SP-X, along with the consumable test kits that run on them. The razor-and-blades logic applies: the machines bring in some money, but the recurring kit sales are the bigger engine over time. For years, Quanterix also ran its own lab-services business, Accelerator, which used its machines to run tests for customers who didn't want to buy the equipment. Under newer leadership, the company has been refocusing on selling instruments and kits to labs rather than operating those services itself, a strategy shift aimed at a steadier, higher-margin business. The most interesting angle here is Alzheimer's blood testing. For a long time, spotting Alzheimer's required brain scans or spinal taps, both expensive and unpleasant. Quanterix's ultra-sensitive assays can find telltale proteins like p-tau217 in a simple blood draw, and that has become a genuine growth area as drugmakers like Eli Lilly and Biogen push new Alzheimer's treatments that need reliable ways to find patients early. That makes Quanterix a picks-and-shovels player in a much bigger fight, though it faces competition from larger diagnostics names such as Roche and Abbott.
Quanterix is still a small, unprofitable company betting that its sensitivity edge translates into a durable franchise, and its results swing on how quickly research labs and drug developers adopt its kits. It is based in Billerica, Massachusetts, just outside Boston's biotech corridor, which puts it close to many of the researchers it serves. The bet is essentially this: if you can measure disease at its earliest whisper, you can catch it sooner — and sell a lot of tests along the way.
Saved answer · last researched 15 Nov 2026